Kouchi Suzuki of Tokyo has hemophilia A. He uses Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] to treat bleeding.
When Kouichi Suzuki was 10 months old, he cut his finger while crawling on the floor and began bleeding uncontrollably. Soon after, he was diagnosed with hemophilia A, the most common form of hemophilia, in which the body does not produce enough of a critical blood-clotting protein called "factor VIII." Without treatment, people with hemophilia A can suffer debilitating joint damage or even death from uncontrollable bleeding.
Suzuki has been using Baxter's ADVATE to help control bleeds since 2007, the year it became available in Japan. Introduced in 2003, ADVATE was approved in 50 countries at the end of 2010, with Peru, Turkey, Kazakhstan and Panama among the markets expected to approve and/or launch ADVATE in 2011.
Growing up in Tokyo, Suzuki did not let his hemophilia interfere with the things he enjoyed most-school, physical education classes and spending time with his friends. He started to self-infuse1 factor VIII in the fourth grade, enabling him to administer the therapy and home and get on with his day.
"Self-infusion made managing hemophilia much easier," Suzuki says. "Even if I had a bleed at school, I didn't have to go to the hospital. I could self-infuse my clotting factor and go back to class."
Now 38 and living in Tokyo with this wife, Megumi, he still maintains that same positive outlook on life. A former computer game developer, Suzuki now develops cellular phone tools and services. In his free time, he is an enthusiastic landscape photographer, and enjoys musicals, plays, and composing various genres of music. His passion for composing runs so deep that he hopes to one day compose music for films.
What advice would he give young people with hemophilia today?
"Don't think you can't do something because you have hemophilia," Suzuki says. "I don't think of it as a disadvantage. Rather, I look at it positively and am enjoying life."
ADVATE HCP Detailed Risk Information
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] is indicated for control and prevention of bleeding episodes in adults and children with hemophilia A and for the peri-operative management in adults and children with hemophilia A.
ADVATE is not indicated for the treatment of von Willebrand's disease.
Important Risk Information for ADVATE therapy
ADVATE is contraindicated in patients with known anaphylaxis to mouse or hamster protein or other constituents of the product.
Allergic-type hypersensitivity reactions, including anaphylaxis, are possible and have been reported with ADVATE. Symptoms have manifested as dizziness, paresthesia, rash, flushing, face swelling, urticaria, dyspnea, and pruritis. Discontinue use if hypersensitivity symptoms occur and administer appropriate emergency treatment.
Patients treated with AHF products should be monitored for the development of factor VIII inhibitors. Inhibitors have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs).
If expected plasma factor VIII levels are not attained, or if bleeding is not controlled with an expected dose, test for the presence of inhibitors.
The most serious adverse reactions seen with ADVATE are hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to factor VIII.
The most common adverse reactions observed in clinical trials (frequency .2% of subjects) were factor VIII inhibitor formation (observed predominantly in PUPs) and headache.
Please see enclosed ADVATE full Prescribing Information.
1 You should be trained on how to do infusions by your hemophilia treatment center or your doctor.